1.

Introduction
Delay of definitive therapy has an unfavourable impact on outcomes in different malignancies [1] [2] [3] . Because most malignant cells appear to grow exponentially with related systemic spread, we can reasonably assume that treatment delay of some tumours may risk missing the window of curability.
Prostate cancer (PCa) is generally considered a relatively slow-growing malignancy, with screening adding a considerable lead time [4, 5] . Delay between diagnosis and active therapy of PCa is often common. Unintended causes for this delay may include the need for pretreatment diagnostics or psychological and logistical reasons. Active surveillance (AS), as opposed to immediate definitive therapy, has garnered considerable support for several reasons in the treatment of low-risk disease. This strategy has introduced a new intended reason for delay in treatment [6, 7] . AS is designed to avoid unnecessary therapy in low-risk PCa, but identification of these tumours can be difficult and may miss the presence of occult higher risk disease.
We review the current medical literature to identify evidence whether treatment delay in PCa results in worse oncologic outcomes. Effects on functional outcome are not addressed.
2.
Evidence acquisition
Study selection
We conducted a systematic review of the electronic databases PubMed and Embase according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement guidelines [8] . Predefined search terms were used to identify articles describing the impact of a delay in treatment or extending the time interval between diagnosis and active curative therapy of PCa on pathologic, biochemical, and mortality outcomes. The literature search included papers published until 30 September 2012. Figure 1 presents the search strategy flowchart. Table 1 lists the terms used in the literature search. References of all retrieved articles were checked for additional cross-references.
Inclusion and exclusion criteria
We limited our search to full-text original articles published in English and available for review. Articles were independently assessed for eligibility using the following predefined criteria:
Study population: Patients diagnosed with PCa Intervention: Surgery: open, laparoscopic, or robotassisted radical prostatectomy; radiation therapy (RT): external-beam RT or brachytherapy Study outcomes: Pathologic characteristics, biochemical recurrence rates (BCRs), or longer term outcomes such as distant metastasis (DM) rates or overall survival (OS) and cancer-specific survival (CSS).
The following studies were excluded: single-arm studies reporting outcomes without direct comparison group (eg, single-arm AS studies) or without subanalysis of the effect of delay, articles only assessing the effect of short intervals (days to weeks) between biopsies and surgery on perioperative outcomes (eg, blood loss, length of surgery, hospital stay), articles presenting overviews of wait times for curative therapy without any of the relevant outcome parameters, and articles presenting the effect of treatment delay on quality of life (QoL) only. Finally, papers outdated by more recent studies using overlapping data sets were excluded.
Data extraction
The following data were extracted from full-text articles by the first author: treatment modality, study design, selection and inclusion criteria, study details (delay definition, patient numbers, differences between groups, and timeto-event analysis details), specific reasons for treatment delay and switch of treatment, and relevant outcomes. Potential biases were analysed and recorded.
Evidence synthesis
Search results
Our literature search identified 17 original articles that were included in the qualitative analysis [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Differences in study design, inclusion criteria, and outcome parameters between studies and the lack of study population details prevented combining data for quantitative analysis. Table 2 presents an overview of the 17 included studies. Four relevant studies were outdated by more recent publications using the same patient study group [26] [27] [28] [29] .
Study analysis
Thirteen studies presented outcomes after RP, 3 after RT, and 1 study combined RP and RT; none were found on brachytherapy. The reports include 34 517 patients with PCa diagnosed from 1981 to 2009. All studies excluded patients with adjuvant therapy. All were retrospectively designed. Summary data occasionally hindered detailed data extraction.
Patient population
Some of these studies focused on patients with low-risk PCa only; others had wider criteria for eligibility (clinical stage T3-4 disease, prostate-specific antigen [PSA] >20, Gleason scores 8-10). Treatment delay was often associated with older patient age or more favourable tumour characteristics (lower D'Amico risk groups, lower PSA, Gleason scores, clinical stage, less positive biopsies). In one study the delayed treatment group actually showed higher Gleason The same search strategy was used in Embase (''[Title/Abstract]'' was replaced by ''ti,ab''). scores but explicitly stated it was due to the effect of repeat biopsies during AS [11] . In general, the number of men receiving immediate treatment was much higher than the number of men undergoing delayed interventions. If described, the staging work-up such as the total number of biopsies differed between studies but not between the direct and delayed treatment groups within one study. Comorbidity status was presented in two studies [13, 22] , with significant differences between groups found in one [13] .
Definition of interval and delay
Treatment delay was defined according to the following definitions: time interval shorter and longer than the median delay time (n = 4; range: 56 d to 3.7 mo), less than or more than a delay of 3 mo (n = 3), analysis per extra month delay (n = 3), <6 mo or >6 mo (n = 2), <60 d or >60 d (n = 2), or comparison of different 3-mo intervals (n = 2). Three studies considered men in the treatment delay category if they were labelled so in the study database; this mainly involved AS-like strategies [13, 23, 25] . One study used treatment delay as a continuous variable for the main analysis (other studies used this variable in subanalyses). It was unclear whether delay was intended or unintended in 11 studies. Two studies reported that the delay group was followed with a fixed AS protocol [11, 25] , two reported on expectant management without fixed criteria [13, 23] , and one stated that AS was frequently applied [16] . Korets et al. excluded men on AS [15] .
3.5.
Definition of outcome/end point
The selected studies used one or more of the following end points as the main outcome variables: PSA BCR rates after radical prostatectomy (RP) or RT (n = 15), pathologic characteristics after RP (n = 8), OS and/or CSS (n = 3), and lymph node or DM rates (n = 2). One study used a previously constructed nomogram predicting the chance of incurable cancer (<75% chance of remaining BCR free 10 yr postsurgery) as the outcome [25] . This was also the only study that did not include any form of a time-to-event analysis. Fourteen studies presented a time-to-event analysis with BCR as the outcome. Of these, seven studies used the time between RP and BCR as the outcome time parameter, four studies used the time between diagnosis and BCR, and one included both. The potential effect on outcomes of this important difference in time-to-event analyses is discussed later. The remaining two studies used other analyses: a landmark analysis in which analysis started at 1 yr after diagnosis for both direct and delayed treatment or binary end point BCR yes or no at a fixed period after treatment for direct or delayed treatment.
Observations of outcome
Seven studies found no significant impact of treatment delay on oncologic outcomes [10, 11, 15, 17, 21, 23, 24] . Two included only men with low-risk disease [11, 23] ADT = androgen-deprivation therapy; AS = active surveillance; BCR = biochemical recurrence; CSS = cancer/cause-specific survival; DM = distance metastasis; DRE = digital rectal examination; ECE = extracapsular extension; ERSPC = European Randomised Study of Screening for Prostate Cancer; HR = hazard ratio; LN = lymph node; NPCR = National Prostate Cancer Registry; OR = odds ratio; OS = overall survival; PCa = prostate cancer; PSA = prostate-specific antigen; PSM = positive surgical margin; RP = radical prostatectomy; RT = radiation therapy; SEER = Surveillance, Epidemiology and End Results; SVI = seminal vesical invasion; TRUS = transrectal ultrasound; WW = watchful waiting.
The longest treatment delay interval was 2.1 yr [23] . Four studies initially suggested an association between treatment delay and outcomes following univariate analysis but not multivariate analysis [14, 16, 18, 25] . Two studies found lower rates of upstaging in the group with delayed therapy [12, 22] . Four studies found that treatment delay had an unfavourable impact; however, none found a relationship of delay with DM, OS, or CSS. Abern et al. noted that if RP was delayed >9 mo, BCR rates and positive surgical margins rates were higher among men with intermediate-risk disease but not among men with low-risk PCa (D'Amico risk classification) [9] . Specific reasons for delay or triggers to switch to active therapy were not presented. Holmströ m et al. found that patients labelled initially as ''expectant management'' in the Swedish National Prostate Cancer Registry had higher Gleason scores in their surgical specimens when compared with men who had undergone surgery at the time of diagnosis (delay of 19.2 mo vs 3.5 mo) [13] . All patients had stage T 2 disease, PSA <20 ng/ml, and Gleason score 6 at diagnosis. Treatment delay resulted from AS in these patients, but the reasons that triggered deferred radical surgery were known (eg, repeat biopsies). Nguyen et al. found that treatment delay >2.5 mo independently predicted time to PSA failure after RT in patients labelled high risk (defined as any of the following criteria: T 2b, PSA >10, Gleason score >6, >34-50% positive biopsy cores) [19] . The authors did not provide reasons for delay or triggers to switch to active therapy. Finally, O'Brien et al. found that in a cohort of men with lowrisk disease, a delay in performing RP >6 mo after diagnosis was associated with a higher frequency of disease upgrading (47% vs 27% upstaging to Gleason score 7-10) and lower PSA progression-free survival rates [20] . Again, no specific reasons for treatment delay or triggers to undergo active therapy were provided.
Besides the effect of treatment delay, most studies included information on the known risk factors for worse pathologic and BCR outcomes after RP or RT.
Study evaluation
This review included studies monitoring the effect of PCa treatment delay on oncologic outcome. Most did not find any differences in outcomes between patients who received immediate or delayed RP or RT according to different definitions of delay. All are limited in varying degrees by suboptimal study design including unaccounted potential biases in the time-to-event analysis. Four studies did find a significant relation in multivariate analysis [9, 13, 19, 20] , of which two included intermediate-to high-risk PCa. One study found an unfavourable effect of delay of RP >9 mo in intermediate-risk disease groups, and one found worse outcomes in non-low-risk disease of RT >2.5 mo after diagnosis [9, 19] . These two studies suggest that in men with non-low-risk disease, oncologic outcomes may be compromised if treatment is delayed. The two other studies that showed a significantly unfavourable outcome associated with treatment delay included low-risk patients only [13, 20] . Selection bias in these two studies very likely accounts for this contrary conclusion. In the article by Holmströ m et al., patients in the delayed treatment group (19.2 mo vs 3.5 mo) are labelled as ''expectant management'' [13] . The reasons why patients switched to active therapy were unclear. We hypothesise that men who initially chose expectant management may have subsequently developed unfavourable disease characteristics on repeat biopsies that resulted in their selection for RP. A similar selection bias might explain the large differences in Gleason upgrading between men undergoing direct RP and delayed RP (27% vs 47% for <6 mo vs 6 mo delay) in the study presented by O'Brien et al. [20] . No reasons for delaying treatment were provided in this study that included recently treated patients with low-risk disease. Again, men may have been included who underwent repeat prostate biopsies as part of an AS-like protocol resulting in pathologic risk reclassification and deferred treatment. Dall'Era et al. specifically cite this potential bias when analysing outcomes [11] . They used the most recent prostate biopsies when comparing outcomes between men undergoing immediate or delayed therapy. Treatment delay did not affect men with low-risk tumours in this study. This selection bias, as hypothesised earlier, probably does not explain the negative effect of treatment delay on non-lowrisk disease because these patients are generally considered unsuitable for AS.
The contradictory protective effect of treatment delay as presented in two studies is also likely to be caused by selection bias [12, 22] . Tumours with more favourable characteristics are often treated later and show more favourable outcomes.
Differences in comorbidity may also introduce potential biases between patients receiving direct versus delayed treatment. Patients with more comorbidity may be more likely to be selected for initial expectant management. This may artificially favour BCR or mortality outcomes after deferred treatment because these patients will succumb to non-PCa causes earlier than healthy men. This bias was noted in both studies presenting comorbidity scores.
Most studies used pathologic characteristics and BCR as the surrogate end points rather than DM, CSS, or OS. However, these surrogate end points have been found to show a significant correlation with metastatic and mortality rates [30] .
Unfortunately, the quality of the evidence in these studies is low. The retrospective design and lack of randomisation cause these studies to be rated level 3. Furthermore, only a few of these studies included patients with unfavourable (intermediate-or high-risk) disease. Most studies show evidence of a selection bias in which patients with more unfavourable risk disease and who are younger are treated earlier than older men and those men with comorbidities. Most studies failed to provide information why patients were treated later or what triggers were used to initiate delayed therapy. It is therefore not possible to generalise findings from single studies or to draw definitive conclusions on the timing of curative treatment for PCa.
Although most included studies failed to reject the null hypothesis that there is no difference in outcomes between immediate and delayed treatment, this does not necessarily imply that we should accept the hypothesis. The power of most studies to reject the null hypothesis may have been too low.
Time-to-event analyses
Fourteen studies presented a time-to-event analysis with BCR as the outcome. Different starting points (t = 0 at the moment of diagnosis versus t = 0 at the moment of treatment) in these analyses may lead to considerable bias. Only 4 of 14 studies identified this potential bias in choosing a specific time-to-event analysis [9, 18, 23, 24] . For example, consider two patients with occult metastases at diagnosis that will grow to clinically detectable BCR, independent of the specific local treatment. The first receives RP at 3 mo after diagnosis, and the second patient at 9 mo after diagnosis.
If the moment of RP is used as the starting point of the time-to-event analysis and BCR occurs at 12 mo after diagnosis, BCR will occur at 9 mo and 3 mo after RP, respectively. This artificially increased time to recurrence may lead to a bias with more favourable results in the early treatment group.
If the moment of diagnosis is used as the starting point of the time-to-event analysis and PSA would start to rise at 6 mo in both patients, the problem is that the first patient shows BCR at 3 mo after diagnosis, whereas the second is not even at risk for BCR. Such an analysis may be biased in favour of delayed surgery.
An alternative approach is to use a landmark analysis, as applied in one of the included studies [18] . Time to BCR is measured from a fixed starting point, such as 12 mo, after diagnosis. Patients are excluded if they are treated after the landmark time but also if they develop BCR before the landmark. This method may bias results in favour of early surgery because patients who develop disease recurrence rapidly would be excluded if they underwent early surgery but not if surgery was delayed.
BCR may also be used as a binary end point (yes vs no) at different time points after treatment [24] . This method may introduce the same bias in which early treatment leads to more favourable results due to an artificial longer time until BCR. If the patients were treated at 3 and 9 mo after diagnosis and had a BCR at 18 mo after diagnosis but were analysed at 12 mo after treatment, the patient treated early would not show BCR, whereas the patient treated later would show BCR at this point. In analyses at 2 yr, however, this bias would be drastically reduced. Therefore the bias introduced in this last analysis may be the smallest.
3.9.
Selection for treatment
The spectrum of clinical progression among men with PCa is very wide and depends on both disease-specific and [31] . PCa with favourable disease features at the time of diagnosis, however, has been shown to have a relatively benign course in most cases, even when diagnosed clinically [32] . Screening for PCa results has advanced the date of diagnosis up to 10-15 yr for men with low-risk tumours [5] . Radical treatment for men with these malignancies may not lead to lower rates of metastases or lower PCa mortality, especially in older men or men with comorbidities. The results of the Prostate Cancer Intervention versus Observation Trial support this concept [33] . In this trial 731 men with localised PCa were randomised to either observation or RP. No differences were found regarding OS or CSS through 12 yr of follow-up. Patients in the intervention group received RP a median of 35 d after randomisation. A subanalysis of the Prostate Cancer Intervention versus Observation Trial study showed that in men with intermediate-and high-risk disease, OS was improved with RP compared with observation [33] .
For the reasons cited earlier, many clinicians have advocated initial AS strategies instead of radical treatment [6, 7, 34] .
Clinical implications
A delay of several months or even years from diagnosis to definitive therapy in men with low-risk PCa is very unlikely to have any unfavourable impact on morbidity or PCa mortality. This is not surprising considering the favourable natural history of low-risk PCa with long lead times. Most of the studies included in this review are in line with this hypothesis. On the other side of the disease spectrum, however, as also found in this review, the risk of missing the window of curability due to treatment delay is a realistic concern. In patients with high-risk or even intermediaterisk disease, a delay of 2.5-9 mo might unfavourably affect outcomes after radical treatment, although the data on this point were mixed. Due to the limitations of the studies included in this review, it is not possible to reach any conclusions on more specific risk subgroups such as men with intermediate-and high-risk disease. Figure 2 presents schematically the effect of a delay between diagnosis and treatment in men with low-risk and higher risk disease. Treatment delay may risk missing a window of curability in men with higher risk disease but may not have an impact on results among men with lower risk tumours.
For men with intermediate-or high-risk disease, 3 mo appears to be an acceptable period in which treatment choices should be made and additional diagnostic studies and treatment performed. Waiting lists for these patients should ideally not exceed this period.
Some of the included studies specifically mention AS. Others do not present specific reasons for delay, but they can be considered to have unintended reasons for delay instead of AS. Although a similar delay would biologically have the same effect independent of the specific (intended or unintended) reason for delay, findings from this review may not be directly applicable to an AS situation.
The number of men on AS who will experience a pathologic upgrading following repeat biopsies may be as high as 28% [6] . Men thought to have low-risk disease at diagnosis may actually harbour higher risk PC. This upgrading is most likely the result of initial undersampling and is described as risk reclassification rather than disease progression [35] . A tumour initially assumed to be low risk but was reclassified as a higher risk tumour later may have a worse prognosis if treatment is delayed >1 yr [36] . Based on this information, clinicians adopting AS protocols may wish to perform confirmatory studies earlier rather than later [37, 38] . This may especially hold true for patients on AS with more positive biopsy cores and higher PSA density at diagnosis [39] . Most AS protocols recommend repeat biopsies within 1 yr of the initial diagnosis [6] .
Additional considerations
In the United Kingdom the Prostate Testing for Cancer and Treatment study is being conducted [40] . Patients are randomised for treatment including AS. This study may also provide answers on the effect of delay due to AS. Simulation models of differences in outcomes between direct and delayed treatment may provide an alternative to randomised studies. For example, Xia et al. modelled PCa mortality after direct RP versus RP after initial AS [41] . It was found that AS may result in a small decline in CSS but large benefits in QoL in men with low-risk PCa. We did not consider the potentially unfavourable effect of delayed treatment on QoL. Sun et al. noted more postoperative urinary incontinence and erectile dysfunction and associated procedures among men undergoing delayed treatment [22] . Radomski et al. found that the treatment delay due to AS did not increase the risk of urinary incontinence [42] , but Fujita et al. noted an unfavourable effect on erectile function possibly because of repeat biopsies [43] . Waiting for radical treatment may also cause distress, although many patients included in an AS protocol did not show high levels of anxiety [44, 45] . Finally, other potentially negative effects of delaying therapy on physical or psychological domain outcomes are unknown. For example, delaying surgery may miss the opportunity to perform nerve-sparing surgery. Disease upgrading or upstaging after treatment following initial AS may lead to a greater need for secondary treatments, which may have a further unfavourable effect on QoL. The European and American guidelines do not specifically mention the timing of curative therapy for PCa [46, 47] .
Conclusions
Among men with low-risk PCa, a treatment delay of several months or even years does not appear to compromise longterm oncologic results following definitive treatment. Limited data suggest that treatment delay may compromise oncologic outcomes in men with non-low-risk PCa. The overall quality of evidence of included studies was 3.
Curative treatment for low-risk PCa, if indicated at all, is not an urgent matter. This creates a window for additional risk stratification including initial AS. Patients deciding whether to commit to an AS protocol should consider a confirmatory biopsy to decrease the possibility that they may harbour occult higher risk disease. [ ( F i g . _ 2 ) T D $ F I G ] 
